1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Physician Views: Can the launch of ViiV Healthcare’s dolutegravir disrupt Gilead’s dominance in the HIV market?

Physician Views: Can the launch of ViiV Healthcare’s dolutegravir disrupt Gilead’s dominance in the HIV market?

  • August 2013
  • -
  • Firstword Pharma

Summary

Table of Contents

Scope

Based on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later this month (it has a PDUFA date of August 17).

A once-daily integrase inhibitor, dolutegravir has been developed by ViiV Healthcare, a joint venture between GlaxoSmithKline, Pfizer and Shionogi. The drug was granted priority review by the FDA in February having been submitted for regulatory approval in December 2012.
Dolutegravir is poised to become the second available integrase inhibitor, following in the footsteps of Merck & Co.'s Isentress (raltegravir), which was approved in October 2007 and generated global sales of $1.5 billion in 2012.
A key advantage for dolutegravir versus Isentress is its once-daily dosing profile. This is widely expected to support uptake, following Phase III study results (from the SPRING-2 trial), which demonstrated non-inferiority for dolutegravir versus Isentress.
Potential usage of dolutegravir as a first-line therapy option has also been boosted by Phase III data (from the SINGLE study) demonstrating superiority to Gilead Sciences' gold-standard three-drug combination Atripla (when dosed in combination with abacavir and lamivudine) - see ViewPoints: Analysts hike peak forecasts for GlaxoSmithKline, Pfizer and Shionogi HIV drug.
These results triggered analysts to increase their forecasts for dolutegravir, and according to data from Bloomberg, the ViiV drug is expected to generate global sales of $1.1 billion by 2018. Significantly, in head-to-head trials with Atripla, Gilead's newer products Stribild and Complera had only demonstrated non-inferiority. In addition to strong efficacy, analysts have noted the potential for a better resistance profile with dolutegravir (no notable resistance in treatment naive patients versus 2-3 percent for Stribild) and fewer drug-drug interactions (due to it being a non-boosted regimen). Extension study data will provide greater clarity on these issues.
However, although dolutegravir is now positioned as a keenly anticipated market entrant there remain some question marks regarding its commercial outlook. Some analysts have noted, for example, that combination use with Epzicom (abacavir) could prove to be a barrier to uptake (given the safety profile of GlaxoSmithKline's older drug), while dolutegravir may fail to demonstrate sustained superiority versus Atripla over a longer duration of therapy (superiority versus Atripla in the SINGLE study may have also been boosted by higher drop-out rates among patients taking Gilead's drug, a number of analysts have noted).
Others have also argued that despite its status as a seemingly best-in-class integrase inhibitor, there is a chance that physicians could use dolutegravir primarily in Isentress failure patients (similarly as to how newer generation antibiotics are increasingly 'held back' to treat patients who have developed resistance to older drugs). According to consensus forecasts, Isentress sales will reach $1.6 billion in 2013, but stabilise at this level for the next few years.

Reasons to purchase this report

To help gauge a more accurate view on how dolutegravir may shape the HIV market, this week's Physician Views poll will ask US-based infectious disease specialists:

- How aware/informed they are about dolutegravir ahead of its pending PDUFA date
- How they expect the availability of dolutegravir to impact their usage of Gilead’s Stribild
- What percentage of dolutegravir usage they anticipate to occur in Isentress failure patients
- Whether combination use with Epzicom will have any negative impact on their prescribing of the drug
- What percentage of total patients they expect to be prescribing dolutegravir to in two year's time

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Antiviral Drugs Market Analysis By Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitor, Protease Inhibitor), By Application ((HIV, Hepatitis, HSV, Influenza), By Type (Generic, Branded)), And Segment Forecasts, 2014 - 202

Antiviral Drugs Market Analysis By Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitor, Protease Inhibitor), By Application ((HIV, Hepatitis, HSV, Influenza), By Type (Generic, Branded)), And Segment Forecasts, 2014 - 202

  • $ 4950
  • Industry report
  • February 2017
  • by Grand View Research

The global antiviral drugs market is expected to reach a value of USD 69.2 billion by 2025, based on a new report by Grand View Research, Inc. According to the WHO, cases of viral infections increase by ...

Antiviral Drugs - Global Market Outlook (2016-2022)

Antiviral Drugs - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • February 2017
  • by Stratistics MRC

According to Stratistics MRC, the Global Antiviral market is accounted for $42.65 billion in 2016 and is expected to reach $63.11 billion by 2022 growing at a CAGR of 5.8%. Increased count of people across ...

Global Anti-Viral drugs Market Outlook - Market size, Segmentation, Market Share and Competitive Landscape (2017 - 2022)

Global Anti-Viral drugs Market Outlook - Market size, Segmentation, Market Share and Competitive Landscape (2017 - 2022)

  • $ 4250
  • Industry report
  • January 2017
  • by Mordor Intelligence LLP

In 2016, the global antiviral market was estimated to be worth USD 30.84 billion and is expected to reach revenues of approximately USD 40.71 billion by 2022 at a CAGR of 5.71% between 2016 and 2022. The ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the US

  • April 2017
    44 pages
  • Therapy  

    Serotonin Speci...  

    Antidepressant  

  • United States  

View report >

Cell Therapy Industry in the US

  • April 2017
    5 pages
  • Cell Therapy  

    Biomarker  

    Gene Expression  

  • United States  

View report >

Antiviral Market - Forecast

  • April 2017
    3 pages
  • Antiviral  

View report >

Related Market Segments :

Antiviral

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.